The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Extracellular vesicle PD‐L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies
Open accessAbstract
Abstract Programmed cell death 1 ligand 1 (PD-L1) is the ligand for programmed death protein-1 (PD-1), is associated with immunosuppression. Signaling via PD-1/PD-L1 will transmits negative regulatory signals to T cells, inducing T-cell inhibition, reducing CD8 + T-cell proliferation, or promoting T-cell apoptosis, which effectively reduces the immune response and leads to large-scale tumor growth. Accordingly, many antibody preparations targeting PD-1 or PD-L1 have been designed to block the binding of these two proteins and restore T-cell proliferation and cytotoxicity of T cells. However, these drugs are ineffective in clinical practice. Recently, numerous of studies have shown that, in addition to the surface of tumor cells, PD-L1 is also found on the surface of extracellular vesicles secreted by these cells. Extracellular vesicle PD-L1 can also interact with PD-1 on the surface of T cells, leading to immunosuppression, and has been proposed as a potential mechanism underlying PD-1/PD-L1-targeted drug resistance. Therefore, it is important to explore the production, regulation and tumor immunosuppression of PD-L1 on the surface of tumor cells and extracellular vesicles, as well as the potential clinical application of extracellular vesicle PD-L1 as tumor biomarkers and therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tumor cells secrete extracellular vesicles (EVs) having membrane‐bound PD‐L1, mostly to upregulate the PD‐1 mechanism, thus decreasing T lymphocytes [274, 275].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [275]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Han, M., Gu, Y., Lu, P., Li, J., Cao, H., Li, X., Qian, X., Yu, C., Yang, Y., Yang, X., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1145-5 · Cited by 175
Self-citationRetractedZheng, Y., Liu, L., Wang, Y., Xiao, S., Mai, R., Zhu, Z., & Cao, Y. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00575-8 · Cited by 58
RetractedThe biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770
Shedding light on the cell biology of extracellular vesicles
van Niel, G., D'Angelo, G., & Raposo, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.125 · Cited by 8,369
Regulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Ceramide Triggers Budding of Exosome Vesicles into Multivesicular Endosomes
Trajkovic, K., Hsu, C., Chiantia, S., Rajendran, L., Wenzel, D., Wieland, F., Schwille, P., Brügger, B., & Simons, M. (2008) · Science · doi:10.1126/science.1153124 · Cited by 3,627
Wound repair and regeneration: Mechanisms, signaling, and translation
Eming, S. A., Martin, P., & Tomic-Canic, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009337 · Cited by 3,562
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J. P., Primdal-Bengtson, B., Dingli, F., Loew, D., Tkach, M., & Théry, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521230113 · Cited by 3,426
Research works printed but not linked: 5
- Liu C, Gao AC. IFNgamma, a double-edged sword in cancer immunity and metastasis. Cancer Res. 2019;79:1032–3. · DOI
- Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I. Dual faces of IFNgamma in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin Cancer Res. 2016;22:2329–34. · DOI · Paper page
- Ju X, Zhang H, Zhou Z, Chen M, Wang Q. Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-a signaling. Exp Cell Res. 2020;396:112315. · DOI
- Ni XY, Sui HX, Liu Y, Ke SZ, Wang YN, Gao FG. TGF-beta of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation. Oncol Rep. 2012;28:615–21. · DOI
- Guo R, Li Y, Wang Z, Bai H, Duan J, Wang S, Wang L, Wang J. Hypoxia-inducible factor-1alpha and nuclear factor-kappaB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells. Cancer Sci. 2019;110:1665–75. · DOI
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Serrano, D. R., Juste, F., Anaya, B. J., Ramirez, B. I., Sánchez-Guirales, S. A., Moyota, J. M. Q., Hernandez, E. M., Simon, J. A., Trallero, J. M., Serrano, C., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101336 · Cited by 143
“Also, in melanoma/mouse models, administration of exosomes with PD-L1 promotes tumor growth and reduces tumor-infiltrating CD8 + T cell [25].”
PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders
Lee, D., Cho, M., Kim, E., Seo, Y., & Cha, J. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.026 · Cited by 131
“142 In contrast, some reports have shown a correlation between exosomal PD-L1 levels and ICB treat-ment ef fi cacy; however, the results vary across different cancer types and cohorts, 143 – 145 leading to a lack of consistent evidence.”
Wang, N.-H., Lei, Z., Yang, H.-N., Tang, Z., Yang, M., Wang, Y., Sui, J.-D., & Wu, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6049 · Cited by 119
“EV PD-L1-induced immune evasion has been verified in different types of tumors, such as NSCLC, prostate, breast, gastric, head, and neck cancer, among others (112).”
Engineered EVs designed to target diseases of the CNS
Nieland, L., Mahjoum, S., Grandell, E., Breyne, K., & Breakefield, X. O. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.009 · Cited by 100
Metadata
- Authors
- Liu, J., Peng, X., Yang, S., Li, X., Huang, M., Wei, S., Zhang, S., He, G., Zheng, H., Fan, Q., Yang, L., & Li, H.
- Affiliations
- Fourth Affiliated Hospital of China Medical University (CN)
- Corresponding author
- Yang, Liang
- Li, Hangyu
- ORCID
- Venue
- Cell Communication and Signaling
- Published
- 2022-01-28
- Volume
- 20
- Issue
- 1
- Pages
- 14-14
- ISSN
- 1478-811X (ISSN-L)
- PMC
- PMC8796536
- OpenAlex
- W4210407214
- Cited by
- 75
- References
- 165
- Citations by year
- 2026: 23 · 2025: 20 · 2024: 12 · 2023: 7 · 2022: 13
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cell Communication and Signaling (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81472302)
- Innovative Research Group Project of the National Natural Science Foundation of China (82003040)
- Natural Science Foundation of Liaoning Province (2020-BS-103)
- China Postdoctoral Science Foundation (2020M681016)
- Xingliaoyingcaijihua Project of Liaoning Province (XLYC1902050)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- extracellular vesicles, PD-L1, PD-1/PD-L1 signaling, tumor immune microenvironment, immunosuppression, T cell suppression, tumor markers, therapeutic target, tumor cell secretion
- MeSH terms
- Extracellular Vesicles, Humans, Neoplasms, Biomarkers, Tumor, CD8-Positive T-Lymphocytes, Tumor Microenvironment, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Extracellular vesicle PD‐L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies. https://app.cochat.ai/papers/10.1186/s12964-021-00816-w
- The paper
- Liu, J., Peng, X., Yang, S., Li, X., Huang, M., Wei, S., Zhang, S., He, G., Zheng, H., Fan, Q., Yang, L., & Li, H. (2022). Extracellular vesicle PD‐L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies. Cell Communication and Signaling. https://doi.org/10.1186/s12964-021-00816-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.